Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Structural basis of subtype-selective competitive antagonism for GluN2C/2D-containing NMDA receptors.

Wang JX, Irvine MW, Burnell ES, Sapkota K, Thatcher RJ, Li M, Simorowski N, Volianskis A, Collingridge GL, Monaghan DT, Jane DE, Furukawa H.

Nat Commun. 2020 Jan 22;11(1):423. doi: 10.1038/s41467-020-14321-0.

2.

NMDA receptors containing GluN2C and GluN2D subunits have opposing roles in modulating neuronal oscillations; potential mechanism for bidirectional feedback.

Mao Z, He S, Mesnard C, Synowicki P, Zhang Y, Chung L, Wiesman AI, Wilson TW, Monaghan DT.

Brain Res. 2020 Jan 15;1727:146571. doi: 10.1016/j.brainres.2019.146571. Epub 2019 Nov 28.

PMID:
31786200
3.

Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid.

Irvine MW, Fang G, Sapkota K, Burnell ES, Volianskis A, Costa BM, Culley G, Collingridge GL, Monaghan DT, Jane DE.

Eur J Med Chem. 2019 Feb 15;164:471-498. doi: 10.1016/j.ejmech.2018.12.054. Epub 2018 Dec 28. Review.

4.

The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.

Sapkota K, Dore K, Tang K, Irvine M, Fang G, Burnell ES, Malinow R, Jane DE, Monaghan DT.

Biochem Pharmacol. 2019 Jan;159:140-153. doi: 10.1016/j.bcp.2018.11.018. Epub 2018 Nov 29.

5.

In the Telencephalon, GluN2C NMDA Receptor Subunit mRNA is Predominately Expressed in Glial Cells and GluN2D mRNA in Interneurons.

Alsaad HA, DeKorver NW, Mao Z, Dravid SM, Arikkath J, Monaghan DT.

Neurochem Res. 2019 Jan;44(1):61-77. doi: 10.1007/s11064-018-2526-7. Epub 2018 Apr 12.

6.

Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Burnell ES, Irvine M, Fang G, Sapkota K, Jane DE, Monaghan DT.

J Med Chem. 2019 Jan 10;62(1):3-23. doi: 10.1021/acs.jmedchem.7b01640. Epub 2018 Mar 5. Review.

7.

A single-channel mechanism for pharmacological potentiation of GluN1/GluN2A NMDA receptors.

Chopra DA, Sapkota K, Irvine MW, Fang G, Jane DE, Monaghan DT, Dravid SM.

Sci Rep. 2017 Jul 31;7(1):6933. doi: 10.1038/s41598-017-07292-8.

8.

Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives.

Sapkota K, Irvine MW, Fang G, Burnell ES, Bannister N, Volianskis A, Culley GR, Dravid SM, Collingridge GL, Jane DE, Monaghan DT.

Neuropharmacology. 2017 Oct;125:64-79. doi: 10.1016/j.neuropharm.2017.07.007. Epub 2017 Jul 11.

9.

The NMDA receptor GluN2C subunit controls cortical excitatory-inhibitory balance, neuronal oscillations and cognitive function.

Gupta SC, Ravikrishnan A, Liu J, Mao Z, Pavuluri R, Hillman BG, Gandhi PJ, Stairs DJ, Li M, Ugale RR, Monaghan DT, Dravid SM.

Sci Rep. 2016 Dec 6;6:38321. doi: 10.1038/srep38321.

10.

Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus.

France G, Fernández-Fernández D, Burnell ES, Irvine MW, Monaghan DT, Jane DE, Bortolotto ZA, Collingridge GL, Volianskis A.

Neuropharmacology. 2017 Jan;112(Pt A):76-83. doi: 10.1016/j.neuropharm.2016.08.010. Epub 2016 Aug 12.

11.

GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia.

Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT.

J Pharmacol Exp Ther. 2016 Mar;356(3):702-11. doi: 10.1124/jpet.115.230391. Epub 2015 Dec 16.

12.

Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known NMDA Receptor Allosteric Modulators.

Irvine MW, Fang G, Eaves R, Mayo-Martin MB, Burnell ES, Costa BM, Culley GR, Volianskis A, Collingridge GL, Monaghan DT, Jane DE.

Synthesis (Stuttg). 2015 Jun 1;47(11):1593-1610. doi: 10.1055/s-0034-1380114.

13.

Bidirectional Effect of Pregnenolone Sulfate on GluN1/GluN2A N-Methyl-D-Aspartate Receptor Gating Depending on Extracellular Calcium and Intracellular Milieu.

Chopra DA, Monaghan DT, Dravid SM.

Mol Pharmacol. 2015 Oct;88(4):650-9. doi: 10.1124/mol.115.100396. Epub 2015 Jul 10.

14.

Nedd4 is a specific E3 ubiquitin ligase for the NMDA receptor subunit GluN2D.

Gautam V, Trinidad JC, Rimerman RA, Costa BM, Burlingame AL, Monaghan DT.

Neuropharmacology. 2013 Nov;74:96-107. doi: 10.1016/j.neuropharm.2013.04.035. Epub 2013 Apr 29.

15.

Different NMDA receptor subtypes mediate induction of long-term potentiation and two forms of short-term potentiation at CA1 synapses in rat hippocampus in vitro.

Volianskis A, Bannister N, Collett VJ, Irvine MW, Monaghan DT, Fitzjohn SM, Jensen MS, Jane DE, Collingridge GL.

J Physiol. 2013 Feb 15;591(4):955-72. doi: 10.1113/jphysiol.2012.247296. Epub 2012 Dec 10.

16.

The NMDA receptor as a target for cognitive enhancement.

Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE.

Neuropharmacology. 2013 Jan;64:13-26. doi: 10.1016/j.neuropharm.2012.06.051. Epub 2012 Jul 11. Review.

17.

Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE.

Neurochem Int. 2012 Sep;61(4):581-92. doi: 10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17. Review.

18.

Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors.

Irvine MW, Costa BM, Volianskis A, Fang G, Ceolin L, Collingridge GL, Monaghan DT, Jane DE.

Neurochem Int. 2012 Sep;61(4):593-600. doi: 10.1016/j.neuint.2011.12.020. Epub 2012 Jan 13.

19.

Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.

Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Laube B, Jane DE, Monaghan DT.

Neuropharmacology. 2012 Mar;62(4):1730-6. doi: 10.1016/j.neuropharm.2011.11.019. Epub 2011 Dec 6.

20.

Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.

Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE.

J Med Chem. 2012 Jan 12;55(1):327-41. doi: 10.1021/jm201230z. Epub 2011 Dec 14.

21.

Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo.

Jullienne A, Montagne A, Orset C, Lesept F, Jane DE, Monaghan DT, Maubert E, Vivien D, Ali C.

Mol Neurodegener. 2011 Oct 5;6:68. doi: 10.1186/1750-1326-6-68.

22.

Pharmacology of NMDA Receptors.

Monaghan DT, Jane DE.

In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 12.

23.

A novel family of negative and positive allosteric modulators of NMDA receptors.

Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, Monaghan DT.

J Pharmacol Exp Ther. 2010 Dec;335(3):614-21. doi: 10.1124/jpet.110.174144. Epub 2010 Sep 21.

24.

Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones.

Suárez F, Zhao Q, Monaghan DT, Jane DE, Jones S, Gibb AJ.

Eur J Neurosci. 2010 Aug;32(3):359-67. doi: 10.1111/j.1460-9568.2010.07298.x. Epub 2010 Jul 6.

25.

Regulation of mu opioid receptor internalization by the scaffold protein RanBPM.

Talbot JN, Skifter DA, Bianchi E, Monaghan DT, Toews ML, Murrin LC.

Neurosci Lett. 2009 Dec 11;466(3):154-8. doi: 10.1016/j.neulet.2009.09.048. Epub 2009 Sep 27.

26.

N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.

Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, Lozovaya NA, Jane DE, Monaghan DT.

J Pharmacol Exp Ther. 2009 Nov;331(2):618-26. doi: 10.1124/jpet.109.156752. Epub 2009 Aug 14.

27.

Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons.

Whitney NP, Peng H, Erdmann NB, Tian C, Monaghan DT, Zheng JC.

FASEB J. 2008 Aug;22(8):2888-900. doi: 10.1096/fj.07-104661. Epub 2008 Apr 10.

28.

NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones.

Brothwell SL, Barber JL, Monaghan DT, Jane DE, Gibb AJ, Jones S.

J Physiol. 2008 Feb 1;586(3):739-50. Epub 2007 Nov 22.

29.

Regional variations in NMDA receptor downregulation in streptozotocin-diabetic rat brain.

Bean L, Zheng H, Patel KP, Monaghan DT.

Brain Res. 2006 Oct 18;1115(1):217-22. Epub 2006 Aug 30.

PMID:
16938282
30.

Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil.

Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT.

J Pharmacol Exp Ther. 2006 May;317(2):606-14. Epub 2006 Jan 5.

PMID:
16397090
31.

Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.

Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT, Jane DE.

J Med Chem. 2005 Apr 7;48(7):2627-37.

PMID:
15801853
32.

Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket.

Kinarsky L, Feng B, Skifter DA, Morley RM, Sherman S, Jane DE, Monaghan DT.

J Pharmacol Exp Ther. 2005 Jun;313(3):1066-74. Epub 2005 Mar 2.

PMID:
15743930
33.

The effect of competitive antagonist chain length on NMDA receptor subunit selectivity.

Feng B, Morley RM, Jane DE, Monaghan DT.

Neuropharmacology. 2005 Mar;48(3):354-9. Epub 2005 Jan 25.

PMID:
15721167
34.

An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance.

Shimoyama N, Shimoyama M, Davis AM, Monaghan DT, Inturrisi CE.

J Pharmacol Exp Ther. 2005 Feb;312(2):834-40. Epub 2004 Sep 23.

PMID:
15388787
35.

Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus.

Lozovaya NA, Grebenyuk SE, Tsintsadze TSh, Feng B, Monaghan DT, Krishtal OA.

J Physiol. 2004 Jul 15;558(Pt 2):451-63. Epub 2004 May 14.

36.

Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.

Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT.

Br J Pharmacol. 2004 Feb;141(3):508-16. Epub 2004 Jan 12.

37.
38.

Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction.

Hrabetova S, Serrano P, Blace N, Tse HW, Skifter DA, Jane DE, Monaghan DT, Sacktor TC.

J Neurosci. 2000 Jun 15;20(12):RC81.

39.

Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase.

Glover RT, Angiolieri M, Kelly S, Monaghan DT, Wang JY, Smithgall TE, Buller AL.

J Biol Chem. 2000 Apr 28;275(17):12725-9.

40.
41.
42.

Molecular determinants of NMDA receptor pharmacological diversity.

Monaghan DT, Andaloro VJ, Skifter DA.

Prog Brain Res. 1998;116:171-90. Review. No abstract available.

PMID:
9932377
43.

ERK2 activation by homocysteine in vascular smooth muscle cells.

Brown JC, Rosenquist TH, Monaghan DT.

Biochem Biophys Res Commun. 1998 Oct 29;251(3):669-76.

PMID:
9790967
44.

Evidence for a causative role of N-methyl-D-aspartate receptors in an in vitro model of alcohol withdrawal hyperexcitability.

Thomas MP, Monaghan DT, Morrisett RA.

J Pharmacol Exp Ther. 1998 Oct;287(1):87-97.

PMID:
9765326
45.

[3H]homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site.

Brown JC 3rd, Tse HW, Skifter DA, Christie JM, Andaloro VJ, Kemp MC, Watkins JC, Jane DE, Monaghan DT.

J Neurochem. 1998 Oct;71(4):1464-70.

46.

Survival and functional demonstration of interregional pathways in fore/midbrain slice explant cultures.

Thomas MP, Webster WW, Norgren RB Jr, Monaghan DT, Morrisett RA.

Neuroscience. 1998 Jul;85(2):615-26.

PMID:
9622257
47.

Organotypic brain slice cultures for functional analysis of alcohol-related disorders: novel versus conventional preparations.

Thomas MP, Davis MI, Monaghan DT, Morrisett RA.

Alcohol Clin Exp Res. 1998 Feb;22(1):51-9.

PMID:
9514285
48.

Dextromethorphan and other N-methyl-D-aspartate receptor antagonists are teratogenic in the avian embryo model.

Andaloro VJ, Monaghan DT, Rosenquist TH.

Pediatr Res. 1998 Jan;43(1):1-7.

PMID:
9432105
49.

Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: enhanced excitotoxic potency and selectivity.

Willis CL, Dauenhauer DL, Humphrey JM, Chamberlin AR, Buller AL, Monaghan DT, Bridges RJ.

Toxicol Appl Pharmacol. 1997 May;144(1):45-55.

PMID:
9169068
50.

Supplemental Content

Loading ...
Support Center